Clinical trial
A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab…
NCT00096954 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00096954 |
|---|---|
| Title | A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) |
| Official title | A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) |
| Acronym | EXACT |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | omalizumab (Xolair), placebo |
| Enrollment | 333 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Nov 18, 2004 |
| Last update posted | Jun 14, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: